Journal Article

Delayed surgery for localised and metastatic renal cell carcinoma: a systematic review and meta-analysis for the COVID-19 pandemic

Sathianathen, Niranjan J, Wang Yuding, Mayor Nikhil, Castellani Daniele, Tikkinen Kari, Ficarra Vincenzo, Pirola, Giacomo Maria, Hsiang-Ying, Lee, Liew Matthew Ping Chao, Langer, Wroclawski Marcelo, Chiu, Peter Ka-Fung, Braga, Isaac, Giannarini Gianluca, Teoh, Jeremy Yuen-Chun, Gurung Pratik, Tan Wei Shen, Leow, Jeffrey J, Chen I-Hsuan Alan, Moon, Dora, Liu Zhenbang, Meng, Max, Chan, Vinson Wai-Shun, Orecchia Luca, Ong William Lay Keat, Kamat Ashish, Tan Wei Phin

2021

Overview

PurposeThe COVID-19 pandemic has led to the cancellation or deferment of many elective cancer surgeries. We performed a systematic review on the oncological effects of delayed surgery for patients with localised or metastatic renal cell carcinoma (RCC) in the targeted therapy (TT) era.MethodThe protocol of this review is registered on PROSPERO(CRD42020190882). A comprehensive literature search was performed on Medline, Embase and Cochrane CENTRAL using MeSH terms and keywords for randomised controlled trials and observational studies on the topic. Risks of biases were assessed using the Cochrane RoB tool and the Newcastle–Ottawa Scale. For localised RCC, immediate surgery [including partial nephrectomy (PN) and radical nephrectomy (RN)] and delayed surgery [including active surveillance (AS) and delayed intervention (DI)] were compared. For metastatic RCC, upfront versus deferred cytoreductive nephrectomy (CN) were compared.ResultsEleven studies were included for quantitative analysis. Delayed surgery was significantly associated with worse cancer-specific survival (HR 1.67, 95% CI 1.23–2.27, p < 0.01) in T1a RCC, but no significant difference was noted for overall survival. For localised ≥ T1b RCC, there were insufficient data for meta-analysis and the results from the individual reports were contradictory. For metastatic RCC, upfront TT followed by deferred CN was associated with better overall survival when compared to upfront CN followed by deferred TT (HR 0.61, 95% CI 0.43–0.86, p < 0.001).ConclusionNoting potential selection bias, there is insufficient evidence to support the notion that delayed surgery is safe in localised RCC. For metastatic RCC, upfront TT followed by deferred CN should be considered.

• Publisher: Springer Nature B.V
• Subject: Cancer surgery / Clinical trials / Coronaviruses / COVID-19 / Kidney cancer / Meta-analysis / Metastases / Metastasis / Nephrectomy / Pandemics / Renal cell carcinoma / Surgery / Surgical mesh / Systematic review